- Home
- NXRT vs GERN Comparison
NXRT vs GERN Comparison
Compare NXRT & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NXRT
- GERN
- Stock Information
- Founded
- NXRT 2014
- GERN 1990
- Country
- NXRT United States
- GERN United States
- Employees
- NXRT N/A
- GERN N/A
- Industry
- NXRT Real Estate Investment Trusts
- GERN Biotechnology: Pharmaceutical Preparations
- Sector
- NXRT Real Estate
- GERN Health Care
- Exchange
- NXRT Nasdaq
- GERN Nasdaq
- Market Cap
- NXRT 957.7M
- GERN 853.5M
- IPO Year
- NXRT N/A
- GERN 1996
- Fundamental
- Price
- NXRT $33.90
- GERN $1.57
- Analyst Decision
- NXRT Hold
- GERN Buy
- Analyst Count
- NXRT 6
- GERN 9
- Target Price
- NXRT $41.88
- GERN $5.13
- AVG Volume (30 Days)
- NXRT 123.4K
- GERN 12.4M
- Earning Date
- NXRT 07-29-2025
- GERN 05-07-2025
- Dividend Yield
- NXRT 6.00%
- GERN N/A
- EPS Growth
- NXRT N/A
- GERN N/A
- EPS
- NXRT N/A
- GERN N/A
- Revenue
- NXRT $255,529,000.00
- GERN $116,293,000.00
- Revenue This Year
- NXRT N/A
- GERN $160.12
- Revenue Next Year
- NXRT $5.40
- GERN $55.01
- P/E Ratio
- NXRT N/A
- GERN N/A
- Revenue Growth
- NXRT N/A
- GERN 22264.04
- 52 Week Low
- NXRT $30.98
- GERN $1.17
- 52 Week High
- NXRT $48.37
- GERN $5.34
- Technical
- Relative Strength Index (RSI)
- NXRT 37.04
- GERN 51.71
- Support Level
- NXRT $33.09
- GERN $1.30
- Resistance Level
- NXRT $34.48
- GERN $1.54
- Average True Range (ATR)
- NXRT 0.85
- GERN 0.11
- MACD
- NXRT -0.22
- GERN 0.03
- Stochastic Oscillator
- NXRT 15.45
- GERN 66.67
About NXRT NexPoint Residential Trust Inc.
NexPoint Residential Trust Inc is a real estate investment trust company. Its objectives are to maximize the cash flow and value of properties owned, acquire properties with cash flow growth potential, provide quarterly cash distributions, and achieve long-term capital appreciation for stockholders. The company seeks to achieve these objectives through targeted management and a capex value-add program. It focuses on acquiring multifamily properties in markets with attractive job growth and household formation fundamentals predominantly in the Southeastern and Southwestern United States. The company generates revenue from the rental of multifamily properties.
About GERN Geron Corporation
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.